November 2017 Vol 10, No 8

November 2017 Vol 10, No 8 - Editorial

Mea culpa—I just didn’t get it! I had read multiple front-page articles in the Philadelphia Inquirer over months, but it just did not get past my “bad news” filter.

Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor

JoAnne Foody, MD, Robin S. Turpin, PhD, Beni A. Tidwell, BS, Debra Lawrence, PhD, Kathy L. Schulman, MS

November 2017 Vol 10, No 8 - Clinical, Original Research

Gout is a metabolic disorder that causes flares of arthritis in the joints and occurs with the onset of inflammation as a result of excess serum uric acid in the blood (ie, hyperuricemia) and the deposition of crystals in tissue.

Stakeholder Perspective

The Growing Role of Real-World Evidence in Clinical Decision-Making

by Gary M. Owens, MD

Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors

Rajeev Ayyagari, PhD, Maureen Neary, PhD, MS, Shang Li, MS, Ariel Rokito, BS, Hongbo Yang, PhD, Jipan Xie, MD, PhD, Al B. Benson III, MD, FACP, FASCO

November 2017 Vol 10, No 8 - Business, Original Research

Neuroendocrine tumors (NETs) are rare tumors that consist of a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body.

The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers

Peter R. Fendt, PharmD, MBA, Brian Ung, PharmD, RPh, F. Randy Vogenberg, RPh, PhD

November 2017 Vol 10, No 8 - Industry Trends

In October 2014, ledipasvir plus sofosbuvir (Harvoni) became available in the United States, providing renewed hope for patients with certain chronic hepatitis C virus (HCV) genotypes.

Results 1 - 4 of 4